Castleark Management’s AbbVie ABBV Stock Holding History

Castleark Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$18K	–	329
2020 Q3	$18K	Hold	200	–	–	﹤0.01%	330
2020 Q2	$20K	Buy	+200	New	+$17.6K	﹤0.01%	323
2017 Q1	–	Sell	-1,800	Closed	-$113K	–	368
2016 Q4	$113K	Hold	1,800	–	–	﹤0.01%	353
2016 Q3	$114K	Hold	1,800	–	–	﹤0.01%	352
2016 Q2	$111K	Hold	1,800	–	–	﹤0.01%	350
2016 Q1	$103K	Hold	1,800	–	–	﹤0.01%	351
2015 Q4	$107K	Hold	1,800	–	–	﹤0.01%	370
2015 Q3	$98K	Hold	1,800	–	–	﹤0.01%	354
2015 Q2	$121K	Hold	1,800	–	–	﹤0.01%	361
2015 Q1	$105K	Hold	1,800	–	–	﹤0.01%	347
2014 Q4	$118K	Hold	1,800	–	–	﹤0.01%	333
2014 Q3	$93K	Hold	1,800	–	–	﹤0.01%	305
2014 Q2	$102K	Hold	1,800	–	–	﹤0.01%	312
2014 Q1	$93K	Hold	1,800	–	–	﹤0.01%	305
2013 Q4	$95K	Hold	1,800	–	–	﹤0.01%	311
2013 Q3	$104K	Hold	1,800	–	–	﹤0.01%	336
2013 Q2	$74K	Buy	+1,800	New	+$78.7K	﹤0.01%	305

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Castleark Management's ABBV Position: Q4 2020 in Review

Castleark Management sold out of AbbVie (ABBV) in Q4 2020, closing a stake of 200 shares — an estimated $18K sold.

Castleark Management first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $121K in Q2 2015. 2,599 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

Castleark Management reported no remaining AbbVie position as of Q4 2020 after selling out during the quarter.
Castleark Management sold 200 AbbVie shares in Q4 2020, an estimated $18K.
Castleark Management first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
Castleark Management's AbbVie position peaked at $121K in Q2 2015.
2,599 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Castleark Management's 13F filing for Q4 2020, filed 17 Feb 2021.